Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663782 | 0.92 | FKBP1A (0.47) | NAAAFKBP1ALMNA | |
| SCHEMBL2032601 | 0.82 | NAAA (0.50) | NAAAFKBP1ALMNA | |
| SCHEMBL1663376 | 0.81 | ALDH1A1 (0.51) | — | |
| SCHEMBL1664583 | 0.80 | NAAA (0.51) | NAAAFKBP1ALMNACHRM2CHRM4 | |
| SCHEMBL1664418 | 0.78 | NAAA (0.44) | NAAACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL28457843 | 0.76 | FKBP1A (0.54) | NAAAFKBP1ALMNACHRM2CHRM4 | |
| SCHEMBL27176007 | 0.74 | FKBP1A (0.58) | NAAAFKBP1ALMNA | |
| SCHEMBL1663781 | 0.74 | TSHR (0.51) | FKBP1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL19512246 | 0.73 | FKBP1A (0.51) | NAAAFKBP1ALMNACHRM2CHRM4 | |
| SCHEMBL14974406 | 0.73 | LMNA (0.59) | NAAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011071674-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-2307476-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100113664-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2009152068-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | DDT, PCNA, AADAC | NAAA 509/4885FKBP1A 666/4885LMNA 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.